Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT05039866 ·Status: ENROLLING_BY_INVITATION

A Fabry Disease Gene Therapy Study

NCT04040049 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

NCT04552691 ·Status: APPROVED_FOR_MARKETING

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

NCT02194985 ·Status: COMPLETED ·Phase: PHASE3

4D-310 in Adults With Fabry Disease and Cardiac Involvement

NCT05629559 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

NCT02603562 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190

NCT04455230 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

NCT06114329 ·Status: RECRUITING ·Phase: PHASE2

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742 ·Status: RECRUITING

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

NCT04046224 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

NCT03425539 ·Status: COMPLETED ·Phase: PHASE3

Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease

NCT02800070 ·Status: COMPLETED ·Phase: PHASE1

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

NCT04252066 ·Status: RECRUITING

Fabry Outcome Survey (FOS)

NCT03289065 ·Status: COMPLETED

A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

NCT04281537 ·Status: COMPLETED

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

NCT03135197 ·Status: COMPLETED

Cardiovasculorenal Phenotyping in Fabry Disease Through Noninvasive Testing

NCT05699265 ·Status: TERMINATED

Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity

NCT00106912 ·Status: COMPLETED

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

NCT00140621 ·Status: COMPLETED ·Phase: PHASE4

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

NCT06904261 ·Status: RECRUITING ·Phase: PHASE3

A Study of Fabrazyme in Pediatric Patients With Fabry Disease

NCT00074958 ·Status: COMPLETED ·Phase: PHASE2

Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

NCT02228460 ·Status: COMPLETED ·Phase: PHASE2

A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease

NCT01839526 ·Status: TERMINATED ·Phase: PHASE1

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283959 ·Status: COMPLETED ·Phase: PHASE2